Unnamed: 0,title,date,stock,sentiment
296368.0,Mid-Afternoon Market Update: Dow Turns Higher; Fed Keeps Rates Unchanged,2020-06-10 14:30:00-04:00,CRIS,neutral
296369.0,61 Stocks Moving In Wednesday's Mid-Day Session,2020-06-10 13:31:00-04:00,CRIS,neutral
296370.0,"Mid-Day Market Update: NASDAQ Tops 10,000; Curis Shares Spike Higher",2020-06-10 12:25:00-04:00,CRIS,positive
296371.0,The 'Important Step' For Nano-Cap Biopharma Curis That's Sending Shares Higher,2020-06-10 10:40:00-04:00,CRIS,positive
296372.0,Mid-Morning Market Update: Markets Mostly Lower; United Natural Foods Earnings Beat Views,2020-06-10 10:21:00-04:00,CRIS,positive
296373.0,Curis shares are trading higher after the company announced that the FDA gave clearance for its IND application for CI-8993 monoclonal anti-VISTA antibody.,2020-06-10 08:21:00-04:00,CRIS,positive
296374.0,Curis Announces FDA Clearance Of IND Application For CI-8993 Monoclonal Anti-VISTA Antibody,2020-06-10 08:08:00-04:00,CRIS,neutral
296375.0,20 Healthcare Stocks Moving In Wednesday's Pre-Market Session,2020-06-10 07:35:00-04:00,CRIS,neutral
296376.0,"The Daily Biotech Pulse: Keytruda Setback For Merck, Denali Pulls The Plug On Neurological Asset",2020-06-10 07:30:00-04:00,CRIS,positive
296377.0,34 Stocks Moving in Wednesday's Pre-Market Session,2020-06-10 07:17:00-04:00,CRIS,neutral
296378.0,"Shares of several companies in the broader healthcare sector are trading lower amid market weakness despite recent strength from many names in the space. Equities are down for the session following cautious comments from US Fed Chair Powell, which forecast uncertainty and downside risk. Some regions of the US have extended lockdown restrictions, including Washington D.C.  and Los Angeles County.",2020-05-13 12:49:00-04:00,CRIS,negative
296379.0,"Curis Q1 EPS $(0.280) Up From $(30.000) YoY, Sales $2.709M Beat $2.400M Estimate",2020-05-12 16:04:00-04:00,CRIS,neutral
296380.0,"The Daily Biotech Pulse: NASH Disappointment For Genfit, Novavax Lands $384M CEPI Funding For Coronavirus Vaccine, GW Pharma Earnings",2020-05-12 08:06:00-04:00,CRIS,negative
296381.0,"The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight",2020-05-10 15:40:00-04:00,CRIS,neutral
296382.0,20 Healthcare Stocks Moving In Monday's Pre-Market Session,2020-05-04 07:44:00-04:00,CRIS,neutral
296383.0,"The Daily Biotech Pulse: Genmark Pre-Announces Q1 Outperformance, Sage to Eliminate 53% of Workforce, Keros IPO",2020-04-08 07:53:00-04:00,CRIS,neutral
296384.0,"Curis Q4 EPS $(0.26) Down From $(0.18) YoY, Sales $3.287M Beat $2.4M Estimate",2020-03-19 16:01:00-04:00,CRIS,neutral
296385.0,"The Week Ahead In Biotech: COVID-19 Updates, Tapering Earnings Flow, Eton's Seizure Drug Review",2020-03-15 09:55:00-04:00,CRIS,neutral
296386.0,Curis Reports $30M Common Stock Purchase Deal With Aspire Capital Fund,2020-02-27 09:45:00-05:00,CRIS,neutral
296387.0,"The Daily Biotech Pulse: Gilead Kicks Off Coronavirus Drug Trials, Adcom Nod For Lily, FDA Approves Esperion's Lipid-Lowering Adjunctive Combo Therapy",2020-02-27 07:35:00-05:00,CRIS,positive
296388.0,Curis And Aurigene Announce Amendment Of Collaboration For The Development And Commercialization Of CA-170,2020-02-06 08:32:00-05:00,CRIS,neutral
296389.0,146 Biotechnology Stocks Moving In Thursday's Session,2020-01-23 12:47:00-05:00,CRIS,neutral
296390.0,Curis and DarwinHealth Announce Scientific Collaboration to Characterize Biomarkers and Tumor Subtype Alignments for Fimepinostat in DLBCL and Solid Malignancies,2020-01-13 08:26:00-05:00,CRIS,negative
296391.0,Curis Announces Option And License Agreement With ImmuNext For Development And Commercialization Of Anti-VISTA Antibodies,2020-01-07 08:09:00-05:00,CRIS,positive
296392.0,"The Week Ahead In Biotech: ASH Presentations Pick Up Steam, Correvio Awaits Adcom Ruling",2019-12-07 08:35:00-05:00,CRIS,positive
296393.0,Curis Reports First Demonstration Of Targeting IRAK4 In Patients With Relapsed/Refractory Non-Hodgkin's Lymphoma Results in Anti-Cancer Activity in Ongoing Phase 1 Study,2019-12-06 07:33:00-05:00,CRIS,positive
296394.0,"Curis Reports Safety, Tolerability, Pharmacokinetic Data In Ongoing Phase 1 Study Of Fimepinostat In Combo With Venetoclax",2019-12-06 07:05:00-05:00,CRIS,positive
296395.0,61 Biggest Movers From Yesterday,2019-11-06 04:19:00-05:00,CRIS,neutral
296396.0,54 Stocks Moving In Tuesday's Mid-Day Session,2019-11-05 12:10:00-05:00,CRIS,neutral
296397.0,"Curis Q3 EPS $(0.19) Up From $(0.22) YoY, Sales $2.856M Beat $2.4M Estimate",2019-11-05 07:26:00-05:00,CRIS,neutral
296398.0,"The Daily Biotech Pulse: FDA Nod For Sanofi, BioCryst's Edema Drug In Japan, Myriad's Q1 Disappointment",2019-11-05 06:53:00-05:00,CRIS,negative
296399.0,"Shares of several healthcare companies are trading lower, potentially on recent Democratic primary polls showing Senator Elizabeth Warren in the lead.",2019-09-26 12:43:00-04:00,CRIS,neutral
296400.0,Shares of many pharma/therapeutics stocks trading lower in sympathy with overall market weakness. Reports China is planning to cut prices for widely-used drugs may also be pressuring the sector today.,2019-09-24 14:01:00-04:00,CRIS,negative
296401.0,90 Biggest Movers From Yesterday,2019-08-08 05:17:00-04:00,CRIS,neutral
296402.0,75 Stocks Moving In Wednesday's Mid-Day Session,2019-08-07 13:16:00-04:00,CRIS,neutral
296403.0,"The Daily Biotech Pulse: Novartis Stands By Zolgensma, GW Pharma Q2 Propelled By Epidiolex Sales, Ionis-Akcea Clinical Readout",2019-08-07 07:34:00-04:00,CRIS,neutral
296404.0,Curis shares are trading lower after the company reported worse-than-expected Q2 sales results.,2019-08-06 16:29:00-04:00,CRIS,neutral
296405.0,"Curis Q2 EPS $(0.22) Up From $(0.26) YoY, Sales $2.094M Miss $2.4M Estimate",2019-08-06 16:18:00-04:00,CRIS,negative
296406.0,"The Week Ahead In Biotech: Focus On Earnings Deluge, Mid-Year Clinical Trial Readouts",2019-08-03 10:18:00-04:00,CRIS,neutral
296407.0,"The Week Ahead In Biotech: Pending Clinical Readouts, Earnings Dominate",2019-07-27 14:32:00-04:00,CRIS,negative
296408.0,60 Biggest Movers From Yesterday,2019-07-18 05:03:00-04:00,CRIS,neutral
296409.0,58 Biggest Movers From Yesterday,2019-07-17 04:59:00-04:00,CRIS,neutral
296410.0,41 Stocks Moving In Tuesday's Mid-Day Session,2019-07-16 12:10:00-04:00,CRIS,neutral
296411.0,52 Biggest Movers From Yesterday,2019-07-16 05:15:00-04:00,CRIS,neutral
296412.0,55 Biggest Movers From Yesterday,2019-07-12 05:18:00-04:00,CRIS,neutral
296413.0,Curis Highlights Publication In Nature Cell Biology Identifying Cancer-Causing Form Of IRAK4 In Patients With AML And MDS,2019-06-12 07:06:00-04:00,CRIS,positive
296414.0,"Curis Q1 EPS $(0.3) Misses $(0.18) Estimate, Sales $1.8M Miss $2.4M Estimate",2019-05-14 16:20:00-04:00,CRIS,negative
296415.0,"The Daily Biotech Pulse: Further Delay in Roche's Spark Acquisition, FDA Nod For Regeneron, Solid Biosciences Sinks On Earnings",2019-05-14 07:42:00-04:00,CRIS,positive
296416.0,Curis Regains Compliance With Nasdaq Continued Listing Requirements,2019-04-10 08:02:00-04:00,CRIS,neutral
296417.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Clinical Trials, Earnings And IPOs",2019-03-30 09:32:00-04:00,CRIS,neutral
296418.0,"The Daily Biotech Pulse: FDA Nod For Novartis, Jazz Positive Late-Stage Data For Sleep Disorder Drug, Genfit IPO",2019-03-27 07:52:00-04:00,CRIS,positive
296419.0,"Curis Q4 EPS $(0.18) Beats $(0.21) Estimate, Sales $2.755M Beat $2.6M Estimate",2019-03-26 16:00:00-04:00,CRIS,neutral
296420.0,"Benzinga Pro's Top 10 Most-Searched Tickers For Morning Of Tues., Mar. 26, 2019",2019-03-26 08:19:00-04:00,CRIS,positive
296421.0,"The Daily Biotech Pulse: Japanese Cheer For AbbVie, Myokardia Offering, CytomX CFO Departs",2019-03-26 07:36:00-04:00,CRIS,positive
296422.0,"Earnings Scheduled For March 26, 2019",2019-03-26 04:00:00-04:00,CRIS,neutral
296423.0,What's Driving The Rally In Microcap Biotech Curis?,2019-03-25 12:05:00-04:00,CRIS,neutral
296424.0,Curis Inc shares are trading higher after the company sold a portion of revenue royalties of Erivedge to Oberland Capital for $65 million upfront and up to $70.7 million in future milestone payments.,2019-03-25 09:17:00-04:00,CRIS,positive
296425.0,Curis Sells Portion of Erivedge Royalties to Oberland Capital For $65M Cash Upfront and Up to $70.7M in Royalty Payments,2019-03-25 08:34:00-04:00,CRIS,neutral
296426.0,"Curis Reports First Mesothelioma Patient Enrolled, Dosed In Phase I Study Of CA-170",2019-01-24 07:09:00-05:00,CRIS,neutral
296427.0,"The Daily Biotech Pulse: Legal Victory For Boston Scientific, Alder Gets New CFO, FDA Go-Ahead For BioXcel",2018-12-12 08:07:00-05:00,CRIS,positive
296428.0,"The Daily Biotech Pulse: Management Change At Merck, Jazz Buyback, Arrowhead Earnings",2018-12-11 08:22:00-05:00,CRIS,neutral
296429.0,"The Daily Biotech Pulse: FDA Nod For Roche, Bristol-Myers Hikes Dividend, 2 Biotechs To Debut",2018-12-07 08:04:00-05:00,CRIS,neutral
296430.0,"The Daily Biotech Pulse: AbbVie Halts Lung Cancer Trial, Oncomed Merges With Mereo, Momenta Offering",2018-12-06 07:56:00-05:00,CRIS,negative
296431.0,"Stocks Which Set New 52-Week Low Yesterday, Wed., Nov. 28, 2018",2018-11-29 10:59:00-05:00,CRIS,negative
296432.0,"The Daily Biotech Pulse: Twist In Protagonist Tale, Catalyst's Autoimmune Disorder Drug Approved",2018-11-29 08:09:00-05:00,CRIS,neutral
296433.0,"Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018",2018-11-28 11:54:00-05:00,CRIS,negative
296434.0,"The Daily Biotech Pulse: IntelliPharmaCeutics Generic Antidepressant Gets FDA Nod, GW Pharma Earnings",2018-11-28 07:46:00-05:00,CRIS,neutral
296435.0,"Stocks Which Set New 52-Week Low Yesterday, Mon., Nov. 26, 2018",2018-11-27 11:26:00-05:00,CRIS,negative
296436.0,"The Daily Biotech Pulse: Abeona Fires CEO, Loxo Passes FDA Muster, Bristol-Myers Flunks Lung Cancer Trial",2018-11-27 07:32:00-05:00,CRIS,negative
296437.0,"Stocks Which Set New 52-Week Low The Prior Trading Session, Fri., Nov. 23, 2018",2018-11-26 10:44:00-05:00,CRIS,negative
296438.0,"Stocks Which Set New 52-Week Low The Last Trading Session, Wed., Nov. 21, 2018",2018-11-23 09:09:00-05:00,CRIS,negative
296439.0,"The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall",2018-11-09 07:32:00-05:00,CRIS,neutral
296440.0,"The Daily Biotech Pulse: AbbVie's Leukemia Drug Trial Meets Endpoint, Denali Strikes Collaboration Deal",2018-11-01 07:30:00-04:00,CRIS,negative
296441.0,50 Biggest Movers From Yesterday,2018-10-19 05:50:00-04:00,CRIS,neutral
296442.0,41 Stocks Moving In Thursday's Mid-Day Session,2018-10-18 12:49:00-04:00,CRIS,neutral
296443.0,48 Biggest Movers From Yesterday,2018-10-17 05:53:00-04:00,CRIS,neutral
296444.0,40 Stocks Moving In Tuesday's Mid-Day Session,2018-10-16 12:46:00-04:00,CRIS,neutral
296445.0,"Curis Names James Dentzer CEO Effective Immediately, Replacing Ali Fattaey Who Is Leaving The Company",2018-09-24 16:24:00-04:00,CRIS,positive
296446.0,"Stocks Which Set New 52-Week Low Yesterday, August 21st",2018-08-22 09:11:00-04:00,CRIS,negative
296447.0,"Stocks Which Set New 52-Week Low Tues., Aug. 21, 2018",2018-08-21 14:56:00-04:00,CRIS,negative
296448.0,"Stocks Which Set New 52-Week Low Yesterday, August 15th",2018-08-16 11:15:00-04:00,CRIS,negative
296449.0,"Stocks Which Set New 52-Week Low Yesterday, August 14th",2018-08-15 12:34:00-04:00,CRIS,negative
296450.0,"The Daily Biotech Pulse: Vertex Awaits FDA Verdict, Strongbridge Falls On Offering, ReShape's Woes Continue",2018-08-15 08:48:00-04:00,CRIS,negative
296451.0,"The Daily Biotech Pulse: Denali's Parkinson's Candidate Clears Early-Stage Trials, Dexcom's Strong Quarter",2018-08-02 08:54:00-04:00,CRIS,positive
296452.0,"Curis Q2 EPS $(0.26) Beats $(0.39) Estimate, Sales $2.36M Beat $2.34M Estimate",2018-08-02 07:25:00-04:00,CRIS,neutral
296453.0,"The Week Ahead In Biotech: Conferences, PDUFA Dates, Earnings And IPOs",2018-07-28 14:04:00-04:00,CRIS,neutral
296454.0,"Benzinga's Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index",2018-07-05 07:43:00-04:00,CRIS,neutral
296455.0,"Benzinga's Daily Biotech Pulse: Titan's Parkinson's Disease Drug Implant Trial, Juniper Pharma Sells Itself At 32% Premium",2018-07-03 07:51:00-04:00,CRIS,neutral
296456.0,"Benzinga's Daily Biotech Pulse: Gemphire On Fire, Acceleron-Celgene Taste Success, AbbVie Ditches Galapagos",2018-06-29 08:11:00-04:00,CRIS,positive
296457.0,"Benzinga's Daily Biotech Pulse: Epidiolex, Roche's Influenza Drug Gets Priority Review Status, Xeris Jumps On Positive Trial Results",2018-06-26 08:34:00-04:00,CRIS,positive
296458.0,Benzinga Pro's 5 Stocks To Watch Today,2018-06-11 09:32:00-04:00,CRIS,neutral
296459.0,27 Stocks Moving In Thursday's Pre-Market Session,2018-06-07 08:20:00-04:00,CRIS,neutral
296460.0,40 Biggest Movers From Friday,2018-06-04 04:33:00-04:00,CRIS,neutral
296461.0,26 Stocks Moving In Friday's Pre-Market Session,2018-06-01 08:03:00-04:00,CRIS,neutral
296462.0,58 Biggest Movers From Yesterday,2018-06-01 04:47:00-04:00,CRIS,neutral
296463.0,Hearing Suntrust Raises Price Target On Curis To $18,2018-05-31 13:25:00-04:00,CRIS,neutral
296464.0,44 Stocks Moving In Thursday's Mid-Day Session,2018-05-31 12:42:00-04:00,CRIS,neutral
296465.0,Benzinga Pro's 5 Stocks To Watch Today,2018-05-31 08:27:00-04:00,CRIS,neutral
296466.0,28 Stocks Moving In Thursday's Pre-Market Session,2018-05-31 08:22:00-04:00,CRIS,neutral
296467.0,"Curis Reports FDA Fast Track Designation For CUDC-907 Development In Patients With Relapse, Refractory Diffuse Large B-Cell Lymphoma",2018-05-31 07:06:00-04:00,CRIS,neutral
296468.0,30 Stocks Moving In Wednesday's Mid-Day Session,2018-05-30 12:26:00-04:00,CRIS,neutral
296469.0,Curis Announces 1-for-5 Reverse Split to Go Into Effect 5pm ET Today,2018-05-29 10:12:00-04:00,CRIS,neutral
296470.0,"Curis 8-K Shows Board Approved 1-For-5 Reverse Stock Split Effective Tues., May 29, '18",2018-05-22 17:29:00-04:00,CRIS,positive
296471.0,"Curis Q1 EPS $(0.07) Beats $(0.09) Estimate, Sales $2.468M Beat $2.32M Estimate",2018-05-03 07:09:00-04:00,CRIS,neutral
296472.0,"Curis Shares Up 24.4% Following Better-Than Expected Q4 Loss, Sales Beat",2018-03-08 12:03:00-05:00,CRIS,neutral
296473.0,"Curis Reports Q4 EPS $(0.05) vs $(0.09) Est., Sales $3.3M vs $2.4M Est.",2018-03-08 07:07:00-05:00,CRIS,neutral
296474.0,Curis Announces Initiation of Phase 1 Trial of CA-4948,2018-01-17 07:02:00-05:00,CRIS,neutral
296475.0,"Curis DIrector Rubin Buys 25,000 @ Avg Price: $0.98 -Form4",2017-11-16 14:09:00-05:00,CRIS,neutral
296476.0,"CURIS CEO Fattaey Buys 50,000 @ Avg Price: $1.06 -Form4",2017-11-15 10:28:00-05:00,CRIS,neutral
296477.0,"Curis Reports Q3 EPS $(0.21) vs $(0.09) Est., Sales $2.4M vs $2.19M Est.",2017-11-07 07:19:00-05:00,CRIS,neutral
296478.0,"Guggenheim Initiates Coverage On Curis with Buy Rating, Announces $7.00 Price Target",2017-10-24 09:16:00-04:00,CRIS,neutral
296479.0,Curis Announces 20M Share Offering,2017-09-14 07:00:00-04:00,CRIS,positive
296480.0,Curis Announces 20M Share Offering Common Stock,2017-09-13 16:05:00-04:00,CRIS,positive
296481.0,"Curis Reports Q2 EPS $(0.10) vs $(0.09) Est., Sales $2.1M vs $2.08M Est.",2017-08-03 07:53:00-04:00,CRIS,neutral
296482.0,Mid-Day Market Update: Red Hat Rises After Strong Q1 Results; CIRCOR Shares Slide,2017-06-21 12:02:00-04:00,CRIS,positive
296483.0,Curis Spikes to High of $2.30 on Volume,2017-05-10 12:04:00-04:00,CRIS,neutral
296484.0,"Curis Q1 EPS $(0.11) vs $(0.09) Est, Sales $2.1M vs $2.0M Est",2017-05-04 07:28:00-04:00,CRIS,neutral
296485.0,Benzinga's Option Alert Recap From April 17,2017-04-17 16:27:00-04:00,CRIS,positive
296486.0,Option Alert: Curis Sep 5.0 Calls: 990 @  ASK  $0.25: 1000 traded vs 714 OI:  Earnings 5/4 Before Open [est]  $2.57 Ref,2017-04-17 10:59:00-04:00,CRIS,positive
296487.0,25 Stocks Moving In Friday's Pre-Market Session,2017-03-10 08:09:00-05:00,CRIS,neutral
296488.0,15 Biggest Mid-Day Gainers For Thursday,2017-03-09 12:32:00-05:00,CRIS,neutral
296489.0,"Curis Reports Q4 EPS $(0.08) vs $(0.10) in Same Qtr. Last Year, Sales $2.4M vs $2.1M YoY",2017-03-09 07:12:00-05:00,CRIS,neutral
296490.0,"Curis, Aurigene Extend Exclusivity Period With $7.5M Payment To Aurigene",2017-01-09 07:13:00-05:00,CRIS,positive
296491.0,12 Biggest Mid-Day Losers For Monday,2016-11-28 13:05:00-05:00,CRIS,negative
296492.0,16 Stocks Moving In Monday's Pre-Market Session,2016-11-28 08:24:00-05:00,CRIS,neutral
296493.0,Curis Announces Full Approval of Roche's Erivedge in the European Union,2016-11-28 07:00:00-05:00,CRIS,positive
296494.0,"Curis to Offer Early Clinical Pharmacokinetic, Biomarker Data from CA-170 Phase I Trial at SITC Conference",2016-11-09 12:17:00-05:00,CRIS,neutral
296495.0,"Curis Reports Q3 EPS $(0.21) vs. Est. $(0.10), Rev. $1.8M vs. Est. $1.84M",2016-11-03 07:01:00-04:00,CRIS,neutral
296496.0,Mid-Morning Market Update: Markets Open Higher; AutoZone Profit Tops Estimates,2016-09-22 10:30:00-04:00,CRIS,positive
296497.0,"25 Stocks Which Rallied Four Days, Then Sold Off Yesterday",2016-09-22 09:47:00-04:00,CRIS,neutral
296498.0,22 Stocks With Three-Day Increasing Volume,2016-09-21 09:16:00-04:00,CRIS,neutral
296499.0,7 Stocks Which Rallied Three Days On Increasing Volume,2016-09-21 08:54:00-04:00,CRIS,neutral
296500.0,30 Stocks With Three-Day Increasing Volume,2016-09-20 09:10:00-04:00,CRIS,neutral
296501.0,15 Stocks Which Rallied Three Days On Increasing Volume,2016-09-20 08:58:00-04:00,CRIS,neutral
296502.0,"Aurigene Discovery Technologies Ltd Buys 10,208,333 Shares of Curis @$2.40/Share -Form 4",2016-09-09 12:52:00-04:00,CRIS,positive
296503.0,Curis Receives FDA Orphan Drug Designation for CUDC-907 for  Treatment of Nuclear Protein in Testis (NUT) Midline Carcinoma,2016-09-08 09:51:00-04:00,CRIS,neutral
296504.0,"Curis Reports Q2 EPS $(0.09) vs. Est. $(0.09), Rev. $1.7M vs. Est. $2.05M",2016-08-04 07:12:00-04:00,CRIS,neutral
296505.0,Curis Reports Dosing of First Patient in a Phase 1 Trial of CA-170,2016-06-21 07:03:00-04:00,CRIS,neutral
296506.0,Curis Announes NDA Accepted for CA-170,2016-06-01 07:09:00-04:00,CRIS,positive
296507.0,"Curis Q1 EPS ($0.07) vs ($0.08) est, Revenue $1.73M vs $2.3M est",2016-05-09 08:02:00-04:00,CRIS,neutral
296508.0,Cowen & Company Assumes Curis at Outperform,2016-05-05 17:45:00-04:00,CRIS,neutral
296509.0,Curis Reports Publication of CUDC-907 Phase 1 Trial Data in Lancet Oncology,2016-04-04 07:01:00-04:00,CRIS,neutral
296510.0,"SunTrust Robinson Humphrey Initiates Coverage on Curis at Buy, Announces $3.00 PT",2016-03-01 16:25:00-05:00,CRIS,neutral
296511.0,"Curis Reports Q4 EPS $(0.10) Vs Est $(0.12), Sales $2.1M Vs Est $2.98M",2016-02-29 07:07:00-05:00,CRIS,neutral
296512.0,12 Biotechs With Binary Events Coming This Year,2016-01-08 12:13:00-05:00,CRIS,neutral
296513.0,Curis Reports Clinical Activity of CUDC-907 in Patients With DLBCL Harboring MYC Oncogene Alterations at #ASH2015,2015-12-06 19:14:00-05:00,CRIS,neutral
296514.0,"Curis Reports Q3 EPS $(0.04) vs $(0.08) Est., Sales $2.8M vs $2.82M Est.",2015-11-09 07:10:00-05:00,CRIS,neutral
296515.0,Curis Collaborator Aurigene Presents Preclinical Data From Oral Small Molecule PD-L1/VISTA and IRAK4 Programs at AACR-NCI-EORTC Conference,2015-11-08 16:58:00-05:00,CRIS,neutral
296516.0,Curis Announces Oral Presentation of Phase 1 Data for CUDC-907 at 2015 ASH Annual Meeting,2015-11-05 09:25:00-05:00,CRIS,neutral
296517.0,Curis Reports Presentation of Preclinical Data From Small Molecule PD-L1/VISTA and IRAK4 Programs at the AACR-NCI-EORTC International Conference,2015-11-02 07:04:00-05:00,CRIS,neutral
296518.0,Curis Expands Cancer Drug Pipeline With Small Molecule PD-L1/ VISTA Immune Checkpoint Antagonist and IRAK4 Kinase Inhibitors,2015-10-19 07:02:00-04:00,CRIS,negative
296519.0,Curis Spikes to High on Volume,2015-08-13 15:48:00-04:00,CRIS,neutral
296520.0,"FBR Capital Initiates Coverage on Curis at Outperform, Announces $6.00 PT",2015-08-11 07:42:00-04:00,CRIS,neutral
296521.0,"Curis Reports Inline Q2 Loss $0.06, Sales $2.034M",2015-08-06 07:07:00-04:00,CRIS,negative
296522.0,Curis Reports CUDC-907 Shows Objective Responses in Patients With Relapsed/ Refractory DLBCL from Ongoing Phase 1 Trial at ASCO,2015-05-31 09:39:00-04:00,CRIS,neutral
296523.0,Curis Announces Presentations of CUDC-907 and Erivedge(R) Clinical Data at 2015 ASCO Annual Meeting,2015-05-20 07:01:00-04:00,CRIS,neutral
296524.0,Stifel Talks 5 Biotech Stocks,2015-05-14 12:17:00-04:00,CRIS,neutral
296525.0,Curis Reports Q1 Loss $0.30 Vs Est Loss $0.06 May Not Compare Sales $1.671M Vs Est $2.27M,2015-05-07 07:15:00-04:00,CRIS,negative
296526.0,"Friday's After-Hours Movers: Etsy, Cliffs Natural Resources And More",2015-04-17 18:08:00-04:00,CRIS,positive
296527.0,"Curis to Present Data from CUDC-427, IRAK-4 Programs at AACR Annual Meeting",2015-04-14 07:06:00-04:00,CRIS,neutral
296528.0,5 Biotech Stocks Roth Capital Analysts Are Watching,2015-04-08 12:21:00-04:00,CRIS,neutral
296529.0,Morning Market Gainers,2015-04-06 09:41:00-04:00,CRIS,neutral
296530.0,Curis Announces Orphan Drug Designation For CUDC-907,2015-04-06 07:04:00-04:00,CRIS,neutral
296531.0,"Friday After-Hours Movers; Curis Inc., NovaGold Resources Inc.",2015-03-07 07:46:00-05:00,CRIS,neutral
296532.0,Curis Prices $60M Public Offering of Common Stock At $2.75/share,2015-02-25 08:09:00-05:00,CRIS,neutral
296533.0,Curis Announces Common Stock Offering; No Terms Disclosed,2015-02-24 16:03:00-05:00,CRIS,negative
296534.0,Why Cowen & Co Likes Celldex Therapeutics Following Its FDA 'Breakthrough',2015-02-24 10:43:00-05:00,CRIS,positive
296535.0,13G: Aurigene Discovery Reports 16.6% Stake In Curis,2015-01-28 11:53:00-05:00,CRIS,neutral
296536.0,UPDATE: Oppenheimer Raises Price Target On Curis On Aurigene Collaboration,2015-01-22 09:45:00-05:00,CRIS,neutral
296537.0,US Stock Futures Slip Ahead Of Housing-Starts Data,2015-01-21 07:07:00-05:00,CRIS,neutral
296538.0,UPDATE: Curis to issue 17.1M shares of its Common Stock as Up-front Consideration,2015-01-21 06:08:00-05:00,CRIS,positive
296539.0,"Curis, Aurigene Announce Collaboration, License, Option Agreement to Discover, Develop and Commercialize Small Molecule Antagonists for Immuno-Oncology and Precision Oncology Targets",2015-01-21 06:07:00-05:00,CRIS,positive
296540.0,Curis Reports Dosing of First Patient in Phase 1 Trial of CUDC-907 in Patients with Advanced/Relapsed Solid Tumors,2014-12-18 07:26:00-05:00,CRIS,positive
296541.0,"Curis, Inc. Reports Q3 EPS of $(0.06) vs $(0.04) Est; Revenue of $1.76M vs $4.13M Est",2014-11-10 07:13:00-05:00,CRIS,neutral
296542.0,Curis Announces Allowance of U.S. Patent Covering Compounds Targeting HDAC and PI3K Activities in a Single Molecule ,2014-10-28 07:03:00-04:00,CRIS,neutral
296543.0,Events for the Week of Sept. 8-12,2014-09-10 14:34:00-04:00,CRIS,neutral
296544.0," Curis CEO Fattaey Buys 62,890 Shares @$1.60/Share -Form 4",2014-08-28 09:56:00-04:00,CRIS,positive
296545.0,"Curis, Inc. Reports Q2 EPS of $(0.02) vs $(0.05) Est; Revenue of $4.80M vs $3.46M Est",2014-08-07 07:06:00-04:00,CRIS,neutral
296546.0,"Events Scheduled for Week of Jun 23rd to Jun 27th, 2014",2014-06-23 18:25:00-04:00,CRIS,neutral
296547.0,Curis Announces Ali Fattaey President and CEO,2014-06-03 07:03:00-04:00,CRIS,neutral
296548.0,"Curis, Inc. Reports Q1 EPS of $(0.06), Inline; Revenue of $1.28M vs $1.88M Est",2014-05-08 07:12:00-04:00,CRIS,neutral
296549.0,"Curis, Debiopharm Presentation Shows Debio 0932 Demonstrates Anti-tumor Activity at AACR 2014 ",2014-04-08 05:40:00-04:00,CRIS,neutral
296550.0,"Curis, Debiopharm Group Reports Debio 0932 Demonstrated Anti-Tumor Activity",2014-04-07 16:29:00-04:00,CRIS,neutral
296551.0,Morning Market Movers ,2014-03-31 09:40:00-04:00,CRIS,neutral
296552.0,Curis Announces Removal of FDA Partial Clinical Holdon CUDC-427,2014-03-31 07:00:00-04:00,CRIS,neutral
296553.0,"Curis to Present Data for CUDC-907, CUDC-427 and Debio 0932 at AACR Annual Meeting ",2014-03-31 06:41:00-04:00,CRIS,neutral
296554.0,"Curis, Inc. Reports Q4 EPS of $(0.05) vs $(0.08) Est",2014-02-20 07:14:00-05:00,CRIS,neutral
296555.0,UPDATE: Wedbush Initiates Coverage on Curis on Potential of New Oral Therapies,2013-12-06 09:37:00-05:00,CRIS,neutral
296556.0,"Wedbush Initiates Coverage on Curis, Inc. at Outperform, Announces $6.00 PT",2013-12-05 16:55:00-05:00,CRIS,neutral
296557.0,Benzinga's Top #PreMarket Losers,2013-11-06 08:20:00-05:00,CRIS,negative
296558.0,"Bret Jensen Likes Mast Therapeutics, Curis as Speculative Biotech Plays",2013-10-06 09:50:00-04:00,CRIS,positive
296559.0,Curis InitiatesRoche-Sponsored Phase 1b/2 Study of Erivedge in Relapsed/Refractory AML and High Risk MDS ,2013-10-04 07:02:00-04:00,CRIS,positive
296560.0,"Baird Initiates Coverage on Curis, Inc. at Outperform, Announces $7.00 PT",2013-10-02 08:53:00-04:00,CRIS,neutral
296561.0,"Chardan Capital Initiates Coverage on Curis, Inc. at Buy, Announces $6.00 PT",2013-09-30 08:28:00-04:00,CRIS,neutral
296562.0,"Curis Strengthens Leadership Team With Appointments of Jaye Viner, M.D. as Chief Medical Officer and Tania Chander, Pharm.D. as VP of Product Development ",2013-08-13 07:08:00-04:00,CRIS,positive
296563.0,"Curis, Inc. Reports Q2 EPS of $(0.02) vs $(0.05) Est; Revenue of $5.40M vs $4.43M Est",2013-08-05 07:11:00-04:00,CRIS,neutral
296564.0,Curis Initiates Clinical Trial of CUDC-427 In Advanced Malignancies ,2013-07-25 07:04:00-04:00,CRIS,positive
296565.0,Curis Announces the Conditional Approval of Erivedge(R) in the European Union ,2013-07-15 07:07:00-04:00,CRIS,positive
296566.0,Curis Announces U.S. Patent Issuance Strengthening Intellectual Property Position of PI3K-HDAC Inhibitor CUDC-907 ,2013-06-20 07:05:00-04:00,CRIS,positive
296567.0,"Piper Jaffray Maintains Overweight on Curis, Inc., Lowers PT to $6.00",2013-02-20 15:48:00-05:00,CRIS,negative
296568.0,"Curis, Inc. Reports Q4 EPS of $(0.15) vs $(0.08) Est; Revenue of $1.69M vs $2.07M Est",2013-02-20 07:15:00-05:00,CRIS,neutral
296569.0,"Curis Names Ali Fattaey, Ph.D. as President and COO",2013-02-19 07:01:00-05:00,CRIS,neutral
296570.0,"PharmaEngine, Guangzhou BeBetter Medicine Technology Execute Collaboration and Research Agreement ",2013-01-03 06:13:00-05:00,CRIS,positive
296571.0,Curis Issued US Patent  Covering HSP90 Inhibitor Debio 0932 ,2012-12-06 07:18:00-05:00,CRIS,negative
296572.0,A Peek Into The Market Before The Trading Starts,2012-11-28 07:20:00-05:00,CRIS,neutral
296573.0,Curis Announces Worldwide Licensing Rights for IAP Inhibitor GDC-0917 From Genentech ,2012-11-28 06:43:00-05:00,CRIS,negative
296574.0,UPDATE: Stifel Nicolaus Initiates Curis at Hold on Erivedge Sales Outlook  ,2012-11-14 11:22:00-05:00,CRIS,neutral
296575.0,Stifel Nicolaus Initiates Coverage on Curis at Hold,2012-11-14 08:30:00-05:00,CRIS,neutral
296576.0,Stifel Nicolaus Initiates Coverage on Curis at Hold,2012-11-14 08:12:00-05:00,CRIS,neutral
296577.0,Curis Reports Q2 EPS $-0.04 vs $-0.05 Est; Revenues $4.35M vs $3.21M Est,2012-08-02 09:03:00-04:00,CRIS,neutral
296578.0,"Oppenheimer Maintains Curis at Outperform, Lowers PT from $5.50 to $3.50",2012-07-26 15:27:00-04:00,CRIS,negative
296579.0,Curis Reports Q1 EPS $0.03 vs $0.03 Est; Revenues $10.4M vs $9.15M Est,2012-05-08 07:32:00-04:00,CRIS,neutral
296580.0,Curis Announces Collaborator Roche's Submission of Erivedge for Registration With Australian Regulatory Authority,2012-05-07 07:08:00-04:00,CRIS,positive
296581.0,"BMO Capital Markets Initiates Coverage on Curis at Outperform, Announces PT of $8",2012-03-13 07:27:00-04:00,CRIS,neutral
296582.0,Debiopharm and Curis Announce Initiation of Phase Ib Expansion Study of HSP90 Inhibitor Debio 0932,2012-02-16 07:03:00-05:00,CRIS,negative
296583.0,UPDATE: MLV Raises Target to $10 on Curis,2012-01-31 10:43:00-05:00,CRIS,neutral
296584.0,Curis Announces FDA Approval of Erivedge(TM) (vismodegib) Capsule as First Treatment for Advanced Basal Cell Carcinoma ,2012-01-30 11:27:00-05:00,CRIS,positive
296585.0,Curis Announces Collaborator Roche's Submission of Marketing Authorization Application for Vismodegib,2011-12-22 07:00:00-05:00,CRIS,neutral
296586.0,Oppenheimer Initiates Coverage on Curis with an Outperform Rating,2011-12-09 08:32:00-05:00,CRIS,neutral
296587.0,"Oppenheimer Initiates Curis at Outperform, $6 PT",2011-12-09 07:03:00-05:00,CRIS,neutral
296588.0,"Rodman & Renshaw Reiterates Curis Market Outperform, $6 PT",2011-11-30 15:11:00-05:00,CRIS,neutral
296589.0,Curis Announces Agreement with The Leukemia & Lymphoma Society to Develop CUDC-907 for Lymphoma and Multiple Myeloma   ,2011-11-30 07:02:00-05:00,CRIS,positive
296590.0,Edison Investment Research Publishes Report on Curis ,2011-11-11 09:01:00-05:00,CRIS,neutral
296591.0,Rodman & Renshaw Maintains Market Outperform Rating and $6 PT on Curis ,2011-11-10 09:28:00-05:00,CRIS,neutral
296592.0,FDA Accepts Curis' NDA; Grants Priority Review,2011-11-09 15:03:00-05:00,CRIS,positive
296593.0,Curis Announces FDA Acceptance and Priority Review of NDA for Vismodegib as Treatment for Advanced Basal Cell Carcinoma  ,2011-11-09 06:39:00-05:00,CRIS,positive
296594.0,Notable Put Options Activity in Curis,2011-09-30 11:34:00-04:00,CRIS,neutral
296595.0,"McNicoll, Lewis & Vlak Initiates Curis at Buy, $8.50 PT",2011-09-22 09:10:00-04:00,CRIS,neutral
296596.0,"Curis, Inc. Announces Appointment of Robert Martell, M.D., Ph.D. to its   Board of Directors",2011-09-15 08:01:00-04:00,CRIS,neutral
296597.0,Curis Announces Submission of New Drug Application by Collaborator Genentech for Vismodegib in Advanced Basal Cell Carcinoma  ,2011-09-12 07:03:00-04:00,CRIS,positive
296598.0,Curis Announces Dosing of First Patient in Phase I CUDC-101 Head and Neck Cancer Combination Trial ,2011-08-16 08:01:00-04:00,CRIS,negative
296599.0,"Rodman & Renshaw Reiterates Curis Market Outperform, $6 PT",2011-07-29 11:33:00-04:00,CRIS,neutral
296600.0,"Rodman & Renshaw Outperform On Curis, Inc.",2011-06-21 13:56:00-04:00,CRIS,neutral
296601.0,"Benzinga's Top Pre-Market NASDAQ Gainers (EXPE, CRIS, STX, NXPI)",2011-04-08 08:09:00-04:00,CRIS,positive
296602.0,Curis Announces Investigator-Initiated Phase II Study Results Presented at 102nd AACR Annual Meeting   ,2011-04-04 08:06:00-04:00,CRIS,neutral
296603.0,Curis Trading Significantly Higher Today (CRIS),2011-03-21 10:24:00-04:00,CRIS,neutral
296604.0,"Morning Market Movers (CRIS, OXPS, SMIT, TGE)",2011-03-21 09:47:00-04:00,CRIS,neutral
296605.0,"Benzinga's Top Pre-Market NASDAQ Gainers (TGE, CRIS, MGIC, VOD)",2011-03-21 08:13:00-04:00,CRIS,positive
296606.0,"Best Biotech Stocks To Own Now (CRIS, CGEN, SPPI, IPXL)",2011-01-13 10:27:00-05:00,CRIS,positive
296607.0,5 Bargain Biotech Stocks,2011-01-11 11:11:00-05:00,CRIS,positive
296608.0,CSC Wins $54 Million Contract ,2010-10-18 08:31:00-04:00,CRIS,positive
296609.0,"Benzinga’s Top Pre-Market Gainers (SKIL, MKTAY, CRIS, RIMM)",2010-02-12 08:33:00-05:00,CRIS,positive
296610.0,"New 52-Week High Stocks (FSII, CGEN, MRM, CRIS)",2009-12-28 09:49:00-05:00,CRIS,neutral
296611.0,Insurance Educational Association Enables Working Professionals to Go Back to School With Fall Semester Curriculum,2009-08-10 08:30:00-04:00,CRIS,neutral
